Typicality: | 0.551 |
Saliency: | 0.327 |
to receive placebo | 12 | purpose |
to serelaxin | 8 | other |
within each group | 5 | location |
subject → be randomized in → a 1:1 ratio | 13 |
subject → be randomized → 1:1 | 10 |
subject → be randomized → 2:1 | 7 |
subject → be randomized in → a 2:1 ratio | 4 |
subject → randomize → 1:1 | 3 |
negative | neutral | positive |
0.074 | 0.884 | 0.042 |
Raw frequency | 37 |
Normalized frequency | 0.327 |
Modifier score | 1.000 |
Perplexity | 7.686 |